UNDERSTANDING THE BIOLOGY OF RESIDUAL DISEASE FROM EARLY STAGE HER2 POSITIVE BREAST CANCER TREATED WITH NEOADJUVANT CHEMO AND ANTI-HER2 THERAPY

Grant number: 1123212 | Funding period: 2017 - 2019

Completed

Abstract

Chemotherapy given prior to surgery can often inform us if a breast tumour is sensitive or resistant to therapy by the amount of disease remaining at time of surgery. We have further shown that the immune response is also important in these patients. In this study we propose to analyse the tumour samples that remain after chemotherapy in order to understand possible resistance mechanisms as well as how the immunity influences survival of HER2-positive breast cancer patients

University of Melbourne Researchers